New Zealand markets closed

IPA Jan 2022 7.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.1500-0.1000 (-40.00%)
As of 02:41PM EST. Market open.
Full screen
Previous close0.2500
Open0.1500
Bid0.0500
Ask0.3000
Strike7.50
Expiry date2022-01-21
Day's range0.1500 - 0.1500
Contract rangeN/A
Volume1
Open interest368
  • Business Wire

    ImmunoPrecise Antibodies Announces Grant of Stock Options

    VICTORIA, British Columbia, January 11, 2022--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 7, 2022 its board of directors approved the grant of 170,000 stock options (the "Options") under its stock option plan to acquire up to an aggregate of 170,000 common shares in the capital of IPA ("Common Shares"). The Options were granted to certain officers of IPA. Each Option is

  • Business Wire

    ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration

    VICTORIA, British Columbia, December 20, 2021--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSX VENTURE: IPA) and ChemPartner Biologics Co. Ltd. ("ChemPartner") today announced their global antibody manufacturing collaboration under which ChemPartner will manufacture and supply to IPA’s specifications IPA’s proprietary PolyTope® TATX-03 Therapy, a rationally designed four monoclonal antibody cocktail developed for use in human clinical trial for the potential prevention

  • Business Wire

    ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022

    VICTORIA, British Columbia, December 13, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for second quarter fiscal year 2022, which ended October 31, 2021.